Confounded Complexity: Vitamin D,Parathyroid Hormone,and Metabolic Syndrome in Peritoneal Dialysis

Reis J.P. , von Muhlen D. , Miller E.R. 3rd Relation of 25-hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur J Endocrinol 2008; 159: 41–8.

Kayaniyil S. , Vieth R. , Harris S.B. , Retnakaran R. , Knight J.A. , Gerstein H.C. Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J Clin Endocrinol Metab 2011; 96: 168–75.

Fraser A. , Williams D. , Lawlor D.A. Associations of serum 25-hydroxyvitamin D, parathyroid hormone and calcium with cardiovascular risk factors: analysis of 3 NHANES cycles (2001-2006). PloS one 2010; 5: e13882.

Bouillon R. , Carmeliet G. , Verlinden L. , van Etten E. , Verstuyf A. , Luderer H.F. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726–76.

Wong K.E. , Szeto F.L. , Zhang W. , Ye H. , Kong J. , Zhang Z. Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. Am J Physiol Endocrinol Metab 2009; 296: E820–8.

Tiosano D. , Schwartz Y. , Braver Y. , Hadash A. , Gepstein V. , Weisman Y. The renin–angiotensin system, blood pressure, and heart structure in patients with hereditary vitamin D–resistance rickets (HVDRR). J Bone Miner Res 2011; 26: 2252–60.

Malloy P.J. , Pike J.W. , Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev 1999; 20: 156–88.

Vimaleswaran K.S. , Berry D.J. , Lu C. , Tikkanen E. , Pilz S. , Hiraki L.T. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PloS Med 2013; 10: e1001383.

Wortsman J. , Matsuoka L.Y. , Chen T.C. , Lu Z. , Holick M.F. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690–3. [Erratum in: Am J Clin Nutr 2003; 77:1342]

Drincic A.T. , Armas L.A. , Van Diest E.E. , Heaney R.P. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity (Silver Spring) 2012; 20: 1444–8.

Ahlstrom T. , Hagstrom E. , Larsson A. , Rudberg C. , Lind L. , Hellman P. Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women. Clin Endocrinol (Oxf) 2009; 71: 673–8.

Reis J.P. , von Muhlen D. , Kritz–Silverstein D. , Wingard D.L. , Barrett–Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007; 30: 1549–55.

Bolland M.J. , Grey A.B. , Gamble G.D. , Reid I.R. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab 2005; 90: 1525–30.

Norenstedt S. , Pernow Y. , Brismar K. , Saaf M. , Ekip A. , Granath F. Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur J Endocrinol 2013; 169: 795–804.

Dong J. , Wang Q. , Chen M.H. , Zhao H.P. , Zhu T.Y. , Tian N. Associations between serum intact parathyroid hormone, serum 25-hydroxyvitamin D, oral vitamin D analogs and metabolic syndrome in peritoneal dialysis patients: a multi-center cross-sectional study. Perit Dial Int 2014; 34: 447–55.

Artaza J.N. , Mehrotra R. , Norris K.C. Vitamin D and the cardiovascular system. Clin J Am Soc Nephrol 2009; 4: 1515–22.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; (113): S1–130.

Tepel M. , Armbruster F.P. , Gron H.J. , Scholze A. , Reichetzeder C. , Roth H.J. Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients. J Clin Endocrinol Metab 2013; 98: 4744–51.

Jean G. , Charra B. , Chazot C. Vitamin D deficiency and associated factors in hemodialysis patients. J Ren Nutr 2008; 18: 395–9.

Chertow G.M. , Plone M. , Dillon M.A. , Burke S.K. , Slatopolsky E. Hyperparathyroidism and dialysis vintage. Clin Nephrol 2000; 54: 295–300.

Mottillo S. , Filion K.B. , Genest J. , Joseph L. , Pilote L. , Poirier P. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113–32.

DeFronzo R.A. , Lang R. Hypophosphatemia and glucose intolerance: evidence for tissue insensitivity to insulin. N Engl J Med 1980; 303: 1259–63.

Vashistha T. , Mehrotra R. , Park J. , Streja E. , Dukkipati R. , Nissenson A.R. Effect of age and dialysis vintage on obesity paradox in long-term hemodialysis patients. Am J Kidney Dis 2013;: [Epub ahead of print].

Kalantar–Zadeh K. , Block G. , Humphreys M.H. , Kopple J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793–808.

Del Valle E. , Negri A.L. , Aguirre C. , Fradinger E. , Zanchetta J.R. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 2007; 11: 315–21.

Ishimura E. , Okuno S. , Tsuboniwa N. , Norimine K. , Fukumoto S. , Yamakawa K. Significant positive association between parathyroid hormone and fat mass and lean mass in chronic hemodialysis patients. J Clin Endocrinol Metab 2013; 98: 1264–70.

Drechsler C. , Grootendorst D.C. , Boeschoten E.W. , Krediet R.T. , Wanner C. , Dekker F.W. on behalf of the NECOSAD study group. Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients. Nephrol Dial Transplant 2011; 26: 1340–6.

de Boer I.H. Vitamin D and glucose metabolism in chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 566–72.

Park S.H. , Lindholm B. Definition of metabolic syndrome in peritoneal dialysis. Perit Dial Int 2009; 29(Suppl 2): S137–44.

Li P.K. , Culleton B.F. , Ariza A. , Do J.Y. , Johnson D.W. , Sanabria M. on behalf of the IMPENDIA and EDEN Study Groups. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol 2013; 24: 1889–900.

Choi S.J. , Kim N.R. , Hong S.A. , Lee W.B. , Park M.Y. , Kim J.K. Changes in body fat mass in patients after starting peritoneal dialysis. Perit Dial Int 2011; 31: 67–73.

Shah N. , Bernardini J. , Piraino B. Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 2005; 25: 362–6.

Lertdumrongluk P. , Lau W.L. , Park J. , Rhee C.M. , Kovesdy C.P. , Kalantar–Zadeh K. Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Nephrol Dial Transplant 2013; 28: 2535–45.

Teng M. , Wolf M. , Ofsthun M.N. , Lazarus J.M. , Hernan M.A. , Camargo C.A. Jr. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115–25.

Kerschbaum J. , Vychytil A. , Lhotta K. , Prischl F.C. , Wiesholzer M. , Machhold–Fabrizii V. Treatment with oral active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis. PloS One 2013; 8: e67836.

Ulutas O. , Taskapan H. , Taskapan M.C. , Temel I. Vitamin D deficiency, insulin resistance, serum adipokine, and leptin levels in peritoneal dialysis patients. Int Urol Nephrol 2013; 45: 879–84.